Table 2.
Ongoing prospective randomized controlled trials in gastric cancer surgery
| Study | Country | Start year | Phase | Study design | Inclusion | Sample size | Primary endpoint |
| KLASS-01 | South Korea | 2006 | III | LADG vs ODG | cT1-2/N0 | 1400 | Overall survival |
| JCOG 0912 | Japan | 2010 | III | LADG vs ODG | cT1-2/N0 | 920 | Overall survival |
| JLSSG 0901 | Japan | 2010 | II/III | LADG vs ODG | cT2-4a/N0-2/M0 | II: 180 | II: Morbidity |
| III: 500 | III: Relapse-free survival | ||||||
| KLASS-02 | South Korea | 2011 | III | LADG vs ODG | cT2-4a/N0-4a/M0 | 1050 | 3-yr DFS |
| CLASS-01 | China | 2012 | III | LADG vs ODG | cT2-4a/N0-4a/M0 | 1056 | 3-yr DFS |
| COACT 1001 | South Korea | 2010 | III | LADG vs ODG | cT2-4a/N0-3a/M0 | 204 | Noncompliance rate |
| KRGS | South Korea | 2011 | II | Robot vs Laparoscopy | cT1-3/M0 | 1700 | Surgical outcomes |
| SENORITA | South Korea | 2012 | III | Laparoscopic SNNS | cT1-2/N0/size < 4 cm | 160 | Safety/efficacy |
LADG: Laparoscopy-assisted distal gastrectomy; ODG: Open distal gastrectomy; SNNS: Sentinel node navigation surgery; DFS: Disease-free survival.